logo

For the Inventor, By the Inventor

Kaohsiung, Taiwan

Yun-Ming Wang

This inventor holds 9 USPTO granted patents and 1 published patent application. Top assignees: National Yang Ming Chiao Tung University, Kaohsiung Medical University, Department of Health the Executive Yuan, Republic of China. Active years: 2001-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yun-Ming Wang. Retrieved from https://idiyas.com/inventor/yun-ming-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 55.6

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 33(Granted Patents)


Location History:

  • Fengshan, TW (2014)
  • Hsinchu, TW (2013 - 2017)
  • Kaohsiung, TW (2001 - 2019)

Company Filing History:

goldMedal5 out of 1,247 
 
National Yang Ming Chiao Tung University
 patents
silverMedal3 out of 147 
 
Kaohsiung Medical University
 patents
bronzeMedal1 out of 2 
 
Department of Health the Executive Yuan, Republic of China
 patents

Years Active: 2001-2019

Loading Chart...
9 patents (USPTO):Explore Patents
1. 10166211 - Nitric oxide releasing compound, pharmaceutical composition, use and synthesis method thereof (2019-01-01),
2. 9738660 - Selective inhibitors for protein kinases and pharmaceutical composition and use thereof (2017-08-22),
3. 8961928 - Ligand and metal complex having the same (2015-02-24),
4. 8877163 - Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes (2014-11-04),
5. 8354512 - Ligand and metal complex (2013-01-15),
6. 8344102 - Nanoparticle and magnetic resonance imaging contrast agent (2013-01-01),
7. 7598335 - Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol) (2009-10-06),
8. 7371728 - Prostate-specific antigen probes for optical imaging (2008-05-13),
9. 6303761 - Triaminepentaacetic acid compound and paramagnetic metal complex prepared from using the compound as ligand (2001-10-16),

Title: Innovations of Inventor Yun-Ming Wang

Introduction

Yun-Ming Wang is a prominent inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that release nitric oxide and selective inhibitors for protein kinases. With a total of 9 patents to his name, his work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents is focused on a nitric oxide releasing compound, along with its pharmaceutical composition, use, and synthesis method. This patent provides a compound designed to release nitric oxide, which is crucial for various biological processes. The compound is described by a specific structural formula, and the patent also outlines a method for treating diseases by administering a therapeutically effective amount of this compound. Another notable patent involves selective inhibitors for protein kinases, which includes a compound formula and its salt forms, aimed at advancing therapeutic options in medicine.

Career Highlights

Yun-Ming Wang has worked at esteemed institutions such as National Yang Ming Chiao Tung University and Kaohsiung Medical University. His academic and research affiliations have allowed him to explore innovative solutions in the pharmaceutical field, contributing to his impressive patent portfolio.

Collaborations

Throughout his career, Yun-Ming Wang has collaborated with notable colleagues, including Gin-Chung Liu and Ting-Jung Chen. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Yun-Ming Wang's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new therapeutic approaches and solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…